Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 11:37AM EDT. Market open.
| Previous close | 65.94 |
| Open | 65.62 |
| Bid | 65.25 x 400 |
| Ask | 65.32 x 400 |
| Day's range | 64.82 - 65.64 |
| 52-week range | 64.63 - 87.87 |
| Volume | |
| Avg. volume | 7,429,945 |
| Market cap | 81.402B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 181.33 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (4.67%) |
| Ex-dividend date | 14 June 2024 |
| 1y target est | N/A |
- Zacks
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- Simply Wall St.
Gilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Gilead Sciences ( NASDAQ:GILD ) First Quarter 2024 Results Key Financial Results Revenue: US$6.69b (up 5.3% from 1Q...
- Investor's Business Daily
Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again
Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
© 2024 Yahoo. All rights reserved.